KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species

Oncotarget

Volumn 8, Issue 9, 2017, Pages 14502-14515

  Pampalakis, Georgios ^a   Sykioti, Vasia Samantha ^b   Ximerakis, Methodios ^b   Stefanakou Kalakou, Ioanna ^a   Melki, Ronald ^c   Vekrellis, Kostas ^b   Sotiropoulou, Georgia ^a,b  

^a UNIVERSITY OF PATRAS   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c CNRS   (France)

Author keywords

Degradomics; In vitro substrates; KLK6; Metalloproteases; synuclein

Indexed keywords

ADAMTS PROTEIN; ADAMTS19 PROTEIN; ADENOVIRUS VECTOR; ALPHA SYNUCLEIN; ENZYME PRECURSOR; KALLIKREIN 6; PRO MATRIX METALLOPROTEINASE 2; RECOMBINANT ENZYME; RECOMBINANT KALLIKREIN 6; UNCLASSIFIED DRUG; KALLIKREIN; PROTEIN KINASE; PRSS18 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BRAIN CELL CULTURE; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; ENZYME ACTIVATION; ENZYME RELEASE; ENZYME SUBSTRATE COMPLEX; EXTRACELLULAR SPACE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SYNUCLEINOPATHY; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PHYSIOLOGY;

ALPHA-SYNUCLEIN; AMP-ACTIVATED PROTEIN KINASE KINASES; ANIMALS; CELLS, CULTURED; EXTRACELLULAR SPACE; KALLIKREINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PROTEIN KINASES; PROTEOLYSIS;

EID: 85014082933     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13264     Document Type: Article

References (46)

1. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 2011; 10:1015-1025.
2. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010; 30:6838-6851.
3. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010; 11:301-307.
4. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012; 338:949-953.
5. Levin J, Giese A, Boetzel K, Israel L, Hogen T, Nubling G, Kretzschmar H, Lorenzl S. Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Exp Neurol. 2009; 215:201-208.
6. Sung JY, Park SM, Lee CH, Um JW, Lee HJ, Kim J, Oh YJ, Lee ST, Paik SR, Chung KC. Proteolytic cleavage of extracellular secreted a-synuclein via matrix metalloproteinases. J Biol Chem. 2005; 280:25216-25224.
7. Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol. 2002; 178:13-20.
8. Kim KS, Choi YR, Park JY, Lee JH, Kim DK, Lee SJ, Paik SR, Jou I, Park SM. Proteolytic cleavage of extracellular alpha-synuclein by plasmin: implications for Parkinson disease. J Biol Chem. 2012; 287:24862-24872.
9. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. 2000 Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA. 2000; 97:4897-4902.
10. Crowther RA, Jakes R, Spillantini MG, Goedert M. 1998. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 1998; 436:309-312.
11. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jakala P, Hartmann T, Price DL, Lee MK. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA. 2005; 102:2162-2167.
12. Iwata A, Maruyama M, Akagi T, Hashikawa T, Kanazawa I, Tsuji S, Nukina N. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet. 2003; 12:2625-2635.
13. Tatebe H, Watanabe Y, Kasai T, Mizuno T, Nakagawa M, Tanaka M, Tokuda T. Extracellular neurosin degrades a-synuclein in cultured cells. Neurosci Res. 2010; 67:341-346.
14. Kasai T, Tokuda T, Yamaguchi N, Watanabe Y, Kametani F, Nakagawa M, Mizuno T. 2008. Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. Neurosci Lett. 2008; 436:52-56.
15. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996; 2:624-636.
16. Scarisbrick IA, Towner MD, Isackson PJ. Nervous systemspecific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 1997; 17:8156-8168.
17. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem. 2000; 33:369-375.
18. Pan S, Zhu D, Quinn JF, Peskind ER, Montine TJ, Lin B, Goodlett DR, Taylor G, Eng J, Zhang J. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics. 2007; 7:469-473.
19. Yuan X, Desiderio DM. Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics. 2005; 5:541-550.
20. Miners JS, Renfrew R, Swirski M, Love S. Accumulation of a-synuclein in dementia with Lewy bodies is associated with decline in the a-synuclein-degrading enzymes kallikrein-6 and calpain-1. Acta Neuropathol Commun. 2014; 2: 164.
21. Spencer B, Michael S, Shen J, Kosberg K, Rockenstein E, Patrick C, Adame A, Masliah E. Lentivirus mediated delivery of neurosin promotes clearance of wild-type alphasynuclein and reduces the pathology in the alpha-synuclein model of LBD. Mol Ther. 2013; 21:31-41.
22. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM. Low CSF levels of both a-synuclein and the a-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One. 2013; 8:e53250.
23. Ximerakis M, Pampalakis G, Roumeliotis T, Sykioti VS, Garbis SD, Stefanis L, Sotiropoulou G, Vekrellis K. Resistance of naturally secreted a-synuclein to proteolysis. FASEB J. 2014; 28:3146-3158.
24. Itoh Y, Binner S, Nagase H. Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J. 1995; 308:645-651.
25. Vekrellis K, Xilouri M, Emmanouilidou E, Stefanis L. Inducible over-expression of wild-type alpha-synuclein in human neuronal cells leads to caspase-dependent nonapoptotic death. J Neurochem. 2009; 109:1348-1362.
26. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudier E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10:39-50.
27. Murphy G, Crabbe T. Gelatinases A and B. Methods Enzymol. 1995; 248:470-484.
28. Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques. 2005; 38:73-83.
29. Bayés A, Tsetsenis T, Ventura S, Vendrell J, Aviles FX, Sotiropoulou G. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem. 2009; 385:517-524.
30. Shahinian H, Loessner D, Biniossek ML, Kizhakkedathu JN, Clements JA, Magdolen V, Schilling O. Secretome and degradome profiling shows that kallikreinrelated peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells. Mol Oncol. 2014; 8:68-82.
31. Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona K, Olieric V, Böckmann A, Meier BH, Melki R. Structural and functional characterization of two alpha-synuclein strains. Nat Commun. 2013; 4: 2575.
32. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V. a-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015; 18:340-344.
33. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM. Exogenous a-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011; 72:51-71.
34. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem. 2009; 284:32989-32994.
35. Bernett MJ1, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M. 2002. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem. 2002; 277:24562-24570.
36. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP. 2003. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun. 2003; 307:948-955.
37. Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT. Calpain-cleavage of a-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol. 2007; 170:1725-1738.
38. Sevlever D, Jiang P, Yen SH. Cathepsin D is the main lysosomal enzyme involved in the degradation of a-synuclein and generation of its C-terminally truncated species. Biochemistry. 2008; 47:9678-9687.
39. Pampalakis G, Arampatzidou M, Amoutzias G, Kossida S, Sotiropoulou G. Identification and analysis of mammalian KLK6 orthologue genes for prediction of physiological substrates. Comput Biol Chem. 2008; 32:111-121.
40. Tapia-González S1, Giráldez-Pérez RM, Cuartero MI, Casarejos MJ, Mena Má, Wang XF, Sánchez-Capelo A. 2011. Dopamine and a-synuclein dysfunction in Smad3 null mice. Mol Neurodegener. 2011; 6:72.
41. Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, Geschwind DH, Glidden DV, Halliday GM, et al. Evidence for a-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci USA. 2015; 112: E5308-17.
42. Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E. 2015. A brain-targeted, modified neurosin (kallikrein-6) reduces a-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener. 2015; 10: 48.
43. Yoon H1, Radulovic M, Wu J, Blaber SI, Blaber M, Fehlings MG, Scarisbrick IA. Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. J Neurochem. 2013; 127:283-98.
44. Sotiropoulou G, Pampalakis G, Prosnikli E, Evangelatos GP, Livaniou E. Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6. Chem Cent J. 2012; 6: 148.
45. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008; 283:23542-23556.
46. Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever O, Wellner UF, Biniossek ML, Stahl A, Lassmann S, Schilling O. Fibroblast activation protein-a, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol Oncol. 2016; 10:40-58.